Bristol-Myers Squibb Company (NYSE:BMY) will report its next earnings on Jan 26 – Jan 30 (Est.). The company reported the earnings of $0.77/Share in the last quarter where the estimated EPS by analysts was $0.65/share. The difference between the expected and actual EPS was $0.12/share, which represents an Earnings surprise of 18.5%.
Many analysts are providing their Estimated Earnings analysis for Bristol-Myers Squibb Company and for the current quarter 19 analysts have projected that the stock could give an Average Earnings estimate of $0.65/share. These analysts have also projected a Low Estimate of $0.49/share and a High Estimate of $0.74/share.
In case of Revenue Estimates, 17 analysts have provided their consensus Average Revenue Estimates for Bristol-Myers Squibb Company as 5.15 Billion. According to these analysts, the Low Revenue Estimate for Bristol-Myers Squibb Company is 4.92 Billion and the High Revenue Estimate is 5.41 Billion. The company had Year Ago Sales of 4.29 Billion.
These analysts also forecasted Growth Estimates for the Current Quarter for BMY to be 71.1%. They are projecting Next Quarter growth of 6.8%. For the next 5 years, Bristol-Myers Squibb Company is expecting Growth of 17.8% per annum, whereas in the past 5 years the growth was 3.57% per annum.
Some buy side analysts are also providing their Analysis on Bristol-Myers Squibb Company, where 5 analysts have rated the stock as Strong buy, 5 analysts have given a Buy signal, 12 said it’s a HOLD, 2 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. 22 Analysts reported that the Price Target for Bristol-Myers Squibb Company might touch $100 high while the Average Price Target and Low price Target is $62.74 and $44.2 respectively.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Bristol-Myers Squibb Company got Downgrade on 11-Aug-16 where investment firm Berenberg Downgrade the stock from Buy to Hold.
Bristol-Myers Squibb Company closed its last trading session at $56.51 with the loss of -0.27%. The Market Capitalization of the company stands at 94.19 Billion. The Company has 52-week high of $77.12 and 52-week low of $49.03. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 2.94% where SMA50 and SMA200 are 5.57% and -11.03% respectively. The Company Touched its 52-Week High on Jul 15, 2016 and 52-Week Low on Oct 25, 2016.
The Relative Volume of the company is 0.75 and Average Volume (3 months) is 13.02 million. Bristol-Myers Squibb Company P/E (price to earnings) ratio is 28.07 and Forward P/E ratio of 18.93.
The company shows its Return on Assets (ROA) value of 10.3%. The Return on Equity (ROE) value stands at 22.7%. While it’s Return on Investment (ROI) value is 4.6%.
While looking at the Stock’s Performance, Bristol-Myers Squibb Company currently shows a Weekly Performance of -0.65%, where Monthly Performance is 10.51%, Quarterly performance is -0.85%, 6 Months performance is -20.62% and yearly performance percentage is -13.88%. Year to Date performance value (YTD perf) value is -16.57%. The Stock currently has a Weekly Volatility of 1.26% and Monthly Volatility of 1.75%.